• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

Omeros Corp (OMER)

Common Shares
Sell: $8.10|Buy: $8.12|Change: 1.73 (-17.55%)

Not yet a customer?

Low cost dealing from £1.50

Choose from our range of SIPP, ISA and Dealing accounts

Find out more

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP

Company profile

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Address

201 Elliott Avenue West
Seattle
WA
USA
98119

Telephone

+1 206 676-5000

Website

https://www.omeros.com

Sector 

Healthcare

Forecast key dates

NameKey Date
Omeros Corp Second Quarter Earnings Conference Call for 20262026-08-14T16:30:00
Omeros Corp Second Quarter Earnings Results for 20262026-08-14T00:00:00
Omeros Corp Annual General Meeting for 20262026-06-26T10:00:00
Omeros Corp First Quarter Earnings Conference Call for 20262026-05-15T16:30:00
Omeros Corp First Quarter Earnings Results for 20262026-05-15T00:00:00
Omeros Corp Fourth Quarter Earnings Conference Call for 20252026-03-31T16:30:00
Omeros Corp Fourth Quarter Earnings Results for 20252026-03-31T00:00:00
Omeros Corp Annual Report for 20252026-03-31T00:00:00
Omeros Corp Third Quarter Earnings Conference Call for 20252025-11-13T16:30:00
Omeros Corp Third Quarter Earnings Results for 20252025-11-13T00:00:00

Previous key dates

NameKey Date
Omeros Corp Second Quarter Earnings Conference Call for 20252025-08-14T16:30:00
Omeros Corp Second Quarter Earnings Results for 20252025-08-14T00:00:00
Omeros Corp Annual General Meeting for 20252025-06-27T10:00:00
Omeros Corp First Quarter Earnings Conference Call for 20252025-05-15T16:30:00
Omeros Corp First Quarter Earnings Result for 20252025-05-15T00:00:00
Omeros Corp Fourth Quarter Earnings Conference Call for 20242025-03-31T16:30:00
Omeros Corp Fourth Quarter Earnings Result for 20242025-03-31T00:00:00
Omeros Corp Annual Report for 20242025-03-31T00:00:00
Omeros Corp Third Quarter Earnings Conference Call for 20242024-11-13T16:30:00
Omeros Corp Third Quarter Earnings Result for 20242024-11-13T00:00:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2025 AJ Bell. All rights reserved.